BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1077 related articles for article (PubMed ID: 1762085)

  • 21. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
    Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM
    Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
    Gram J
    Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ticlopidine facilitates the deaggregation of human platelets aggregated by thrombin.
    Cattaneo M; Akkawat B; Kinlough-Rathbone RL; Packham MA; Cimminiello C; Mannucci PM
    Thromb Haemost; 1994 Jan; 71(1):91-4. PubMed ID: 8165651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity.
    Kumar R; Béguin S; Hemker HC
    Thromb Haemost; 1995 Sep; 74(3):962-8. PubMed ID: 8571330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelets interact with fibrin only after activation.
    Hantgan RR; Taylor RG; Lewis JC
    Blood; 1985 Jun; 65(6):1299-311. PubMed ID: 3888311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ionic and nonionic contrast media on clot structure, platelet function and thrombolysis mediated by tissue plasminogen activator in plasma clots.
    Carr ME; Carr SL; Merten SR
    Haemostasis; 1995; 25(4):172-81. PubMed ID: 7557656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
    Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation.
    Martínez C; Rivera J; Loyau S; Corral J; González-Conejero R; Lozano ML; Vicente V; Anglés-Cano E
    Thromb Haemost; 2001 Apr; 85(4):686-93. PubMed ID: 11341506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of flow on lysis of plasma clots in a plasma environment.
    Sakharov DV; Rijken DC
    Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro.
    Seale L; Finney S; Sawyer RT; Wallis RB
    Thromb Haemost; 1997 May; 77(5):959-63. PubMed ID: 9184410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
    Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
    Nielsen VG
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of streptokinase, urokinase, and recombinant tissue plasminogen activator on platelet aggregability and stability of platelet aggregates.
    Terres W; Umnus S; Mathey DG; Bleifeld W
    Cardiovasc Res; 1990 Jun; 24(6):471-7. PubMed ID: 2167173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist.
    Huang TF; Liu CZ; Ouyang CH; Teng CM
    Biochem Pharmacol; 1991 Aug; 42(6):1209-19. PubMed ID: 1888330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT; Francis CW; Marder VJ
    J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aggregation of washed platelets by plasminogen and plasminogen activators is mediated by plasmin and is inhibited by a synthetic peptide disulfide.
    Puri RN; Hu CJ; Matsueda R; Umeyama H; Colman RW
    Thromb Res; 1992 Mar; 65(4-5):533-47. PubMed ID: 1535463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
    Andrew M; Brooker L; Leaker M; Paes B; Weitz J
    Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets.
    Gartner TK; Bennett JS
    J Biol Chem; 1985 Oct; 260(22):11891-4. PubMed ID: 2995350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.